{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:43:04Z","timestamp":1777581784108,"version":"3.51.4"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer is one of the several comorbidities that have been linked with chronic cutaneous inflammatory diseases namely psoriasis\/psoriatic arthritis and hidradenitis suppurativa. Although the chronic inflammatory state, typical of the diseases, may induce pro-tumorigenic effects, the debate whether or not the drugs currently used in clinical practice do in facts increase a patient\u2019s risk of malignancy remains largely unsolved. The therapeutic armamentarium has been greatly enhanced at least in the last two decades with the advent of biologics, a heterogeneous group of laboratory-engineered agents with more in the pipeline, and other targeted small molecules. Among the organ systems, skin results as one of the most commonly affected, non-melanoma skin cancers being the main drug-induced manifestations as side effect in course of these treatments. The objective of the study is to systematically review the cutaneous malignancy risk of the newer therapies through an overview of meta-analyses and observational studies on the topic.<\/jats:p>","DOI":"10.3389\/fonc.2021.687432","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T21:15:25Z","timestamp":1622754925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies"],"prefix":"10.3389","volume":"11","author":[{"given":"Salvatore","family":"Crisafulli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrezia","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Calapai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated Levels of Tumour Necrosis Factor (TNF)-\u03b1, Interleukin (IL)-1\u03b2 and IL-10 in Hidradenitis Suppurativa Skin: A Rationale for Targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"Van Der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated Cytokine Expression in Lesional and Nonlesional Skin in Hidradenitis Suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12016-007-0039-2","article-title":"Immunopathogenesis of Psoriasis","volume":"33","author":"Nickoloff","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00629.x","article-title":"Immunopathogenesis of Psoriasis","volume":"16","author":"Sabat","year":"2007","journal-title":"Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00475-8","article-title":"Treat-to-Target Approach for the Management of Patients With Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations","volume":"11","author":"Gisondi","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e12806","DOI":"10.1111\/dth.12806","article-title":"HIV-Associated Psoriasis: Epidemiology, Pathogenesis, and Management","volume":"32","author":"Ceccarelli","year":"2019","journal-title":"Dermatol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1201\/b12696-15","article-title":"Chronic Inflammation and Cancer","volume":"16","author":"Shacter","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/039463201402700213","article-title":"Carcinoma Cuniculatum in Course of Etanercept: Blocking Autoimmunity But Propagation of Carcinogenesis","volume":"27","author":"Tchernev","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B10","article-title":"Incidence of Cancer Among Patients With Hidradenitis Suppurativa","volume":"137","author":"Lapins","year":"2001","journal-title":"Arch Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.008","article-title":"Vulvar Cancer Association With Groin Hidradenitis Suppurativa: A Large, Urban, Midwestern US Patient Population Study","volume":"80","author":"Rastogi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1346-8138.14698","article-title":"Cancer Risk in 892 089 Patients With Psoriasis in Korea: A Nationwide Population-Based Cohort Study","volume":"46","author":"Lee","year":"2019","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0132496","DOI":"10.1371\/journal.pone.0132496","article-title":"Increased Levels of NF-\u03bab-Dependent Markers in Cancer-Associated Deep Venous Thrombosis","volume":"10","author":"Malaponte","year":"2015","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1422","article-title":"Assessment of\u00a0Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa","volume":"156","author":"Jung","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.16.05287-X","article-title":"T Reatment Patterns With Systemic Antipsoriatic Agents in Childhood Psoriasis: An Italian Database Analysis","volume":"152","author":"Di Lernia","year":"2017","journal-title":"G Ital di Dermatologia e Venereol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.05753-X","article-title":"Real-World Use of Biological Drugs in Patients With Psoriasis\/Psoriatic Arthritis: A Retrospective, Population-Based Study of Years 2010-2014 From Southern Italy","volume":"155","author":"Marcian\u00f2","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3892\/ijmm.2018.3618","article-title":"FOXP3 Expression is Modulated by TGF-\u03b21\/NOTCH1 Pathway in Human Melanoma","volume":"42","author":"Skarmoutsou","year":"2018","journal-title":"Int J Mol Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1913102","DOI":"10.1001\/jamanetworkopen.2019.13102","article-title":"Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-Analysis","volume":"2","author":"Bilal","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1265","DOI":"10.32113\/wcrj_20194_1265","article-title":"Global Incidence and Mortality of Skin Cancer by Histological Subtype and its Relationship With the Human Development Index (HDI); an Ecology Study in 2018","volume":"6","author":"Khazaei","year":"2019","journal-title":"WCRJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2046","article-title":"Cancer Risk With Tumor Necrosis Factor Alpha (TNF) Inhibitors: Meta-analysis of Randomized Controlled Trials of Adalimumab, Etanercept, and Infliximab Using Patient Level Data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies Associated With Tumour Necrosis Factor Inhibitors in Registries and Prospective Observational Studies: A Systematic Review and Meta-Analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12491","article-title":"Review Article: Dermatological Complications of Immunosuppressive and Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"38","author":"Moran","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15830","article-title":"Risk of Cancer in Patients With Psoriasis on Biological Therapies: A Systematic Review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2307\/632432","article-title":"Lucian A Selection. Ed. and Trm.D. Macleod. Warminster: Aris and Phillips, 1991. Pp. Iv + 316. \u00a335.00 (Bound), \u00a312.50 (Paper)","volume":"113","author":"Sidwell","year":"1993","journal-title":"J Hell Stud"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"B27","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"B28","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for Examining and Interpreting Funnel Plot Asymmetry in Meta-Analyses of Randomised Controlled Trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy Rates in a Large Cohort of Patients With Systemically Treated Psoriasis in a Managed Care Population","volume":"76","author":"Asgari","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00904-9","article-title":"An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis Across Phase III and Long-Term Extension Studies With Comparison to Real-World Observational Data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and Mortality Rates in Patients With Severe Psoriatic Arthritis Requiring Tumour-Necrosis Factor Alpha Inhibition: Results From the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14068","article-title":"Cohort Study of Malignancies and Hospitalized Infectious Events in Treated and Untreated Patients With Psoriasis and a General Population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0198-x","article-title":"Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results From 7-Year Interim Analysis of the ESPRIT Registry","volume":"7","author":"Menter","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1203475418755998","article-title":"Observe-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States","volume":"22","author":"Papp","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug Safety of Systemic Treatments for Psoriasis: Results From The German Psoriasis Registry Psobest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04044.x","article-title":"Safety of Treatment With Biologics for Psoriasis in Daily Practice: 5-Year Data","volume":"26","author":"Van L\u00fcmig","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of Malignancy With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.038","article-title":"Five-Year Analysis From the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab Treatment for Moderate to Severe Psoriasis A Portion of the Data in This Manuscript Was Presented in at the Fall European Academy of Dermatology and Venereology 2","volume":"73","author":"Menter","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1589643","article-title":"Biologics for Chronic Inflammatory Skin Diseases: An Update for the Clinician","volume":"31","author":"Yiqiu","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"B41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1570161115666171116163816","article-title":"Cardiovascular Risk in Psoriasis: Current State of the Art","volume":"17","author":"Dattilo","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: Which Therapy for Which Patient: Psoriasis Comorbidities and Preferred Systemic Agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e14660","DOI":"10.1111\/dth.14660","article-title":"New Generation Biologics for the Treatment of Psoriasis and Psoriatic Arthritis. State of the Art and Considerations About the Risk of Infection","volume":"34","author":"Ceccarelli","year":"2021","journal-title":"Dermatol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1364692","article-title":"Effectiveness of Etanercept in Children With Plaque Psoriasis in Real Practice: A One-Year Multicenter Retrospective Study","volume":"29","author":"Di Lernia","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-006-9005-3","article-title":"Tnf-\u03b1 in Promotion and Progression of Cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.03.027","article-title":"The Inhibition of TNF-\u03b1 Anti-Tumoral Properties by Blocking Antibodies Promotes Tumor Growth in a Rat Model","volume":"313","author":"Larmonier","year":"2007","journal-title":"Exp Cell Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e13180","DOI":"10.1111\/dth.13180","article-title":"Malignant Melanoma in HIV: Epidemiology, Pathogenesis, and Management","volume":"33","author":"Facciol\u00e0","year":"2020","journal-title":"Dermatol Ther"},{"key":"B49","article-title":"Clinical Presentation and Outcome of Non-AIDS Defining Cancers, in HIV-Infected Patients in the ART-Era: The Italian Cooperative Group on AIDS and Tumors Activity","volume":"19","author":"Berretta","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy Risk and Recurrence With Psoriasis and Its Treatments: A Concise Update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S269446","article-title":"Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study","volume":"12","author":"Berge","year":"2020","journal-title":"Clin Epidemiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1133882","article-title":"Melanoma and non-Melanoma Skin Cancer in Psoriatic Patients Treated With High-Dose Phototherapy","volume":"27","author":"Maiorino","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.32113\/wcrj_20205_1574","article-title":"Beneficial Role of Vitamin D in Common Cancers: Is the Evidence Compelling Enough","volume":"7","author":"IAS","year":"2020","journal-title":"WCRJ"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.08.005","article-title":"Management of Non-Melanoma Skin Cancer in Transplant Recipients","volume":"31","author":"Collins","year":"2019","journal-title":"Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5362","article-title":"Nf-\u03bab Inhibition Is Associated With OPN\/MMP-9 Downregulation in Cutaneous Melanoma","volume":"37","author":"Guarneri","year":"2017","journal-title":"Oncol Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32113\/wcrj_20189_1114","article-title":"Dsl. Epidemiology and Population Attributable Fraction of Melanoma to Ultraviolet Radiation in Asia: An Ecological Study","volume":"5","author":"Goodarzi","year":"2018","journal-title":"Wcrj"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.12.008","article-title":"Malignancy in Psoriatic Disease: Results From Prospective Longitudinal Cohorts","volume":"51","author":"Polachek","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B58","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.clindermatol.2009.03.003","article-title":"Malignancy Concerns With Psoriasis Treatments Using Phototherapy, Methotrexate, Cyclosporin, and Biologics: Facts and Controversies","volume":"28","author":"Naldi","year":"2010","journal-title":"Clin Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The Risk of Squamous Cell and Basal Cell Cancer Associated With Psoralen and Ultraviolet A Therapy: A 30-Year Prospective Study","volume":"66","author":"Stern","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199704103361501","article-title":"Malignant Melanoma in Patients Treated for Psoriasis With Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA)","volume":"336","author":"Stern","year":"1997","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.5.595","article-title":"Consensus Workshop on the Toxic Effects of Long-Term PUVA Therapy","volume":"134","author":"Morison","year":"1998","journal-title":"Arch Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02186.x","article-title":"UVB Phototherapy and Skin Cancer Risk: A Review of the Literature","volume":"44","author":"Lee","year":"2005","journal-title":"Int J Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13555-020-00409-4","article-title":"Long-Term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature","volume":"10","author":"Balak","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18887","article-title":"Methotrexate Treatment for Patients With Psoriasis and Risk of Cutaneous Melanoma: A Nested Case\u2013Control Study","volume":"183","author":"Polesie","year":"2020","journal-title":"Br J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C","article-title":"The Carcinogenic Risk of Treatments for Severe Psoriasis","volume":"73","author":"Stern","year":"1994","journal-title":"Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of Malignancies in Psoriasis Patients Treated With Cyclosporine: A 5 Y Cohort Study","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1120852","article-title":"Effectiveness and Safety of Cyclosporine in Pediatric Plaque Psoriasis: A Multicentric Retrospective Analysis","volume":"27","author":"Di Lernia","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0251","article-title":"Malignancy After Solid Organ Transplantation: An Overview","volume":"13","author":"Zafar","year":"2008","journal-title":"Oncologist"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.09.018","article-title":"Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Matrixmetalloproteinases Activation is Mediated by Osteopontin Overexpression","volume":"1863","author":"Malaponte","year":"2016","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170208163714","article-title":"Melanoma Adjuvant Treatment: Current Insight and Clinical Features","volume":"18","author":"D`Aniello","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00439-5","article-title":"Biologic Treatment for Hidradenitis Suppurativa","volume":"20","author":"Flood","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1389201021666200505100556","article-title":"Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa","volume":"22","author":"Giuffrida","year":"2020","journal-title":"Curr Pharm Biotechnol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamadermatol.2016.4920","article-title":"Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States","volume":"153","author":"Garrett","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-Analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The Risk of Melanoma and Hematologic Cancers in Patients With Psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.687432\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T21:15:31Z","timestamp":1622754931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.687432\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":75,"alternative-id":["10.3389\/fonc.2021.687432"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.687432","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"article-number":"687432"}}